Assembly Biosciences (ASMB) Competitors $18.40 +0.48 (+2.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.29 -0.11 (-0.60%) As of 08/1/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. NKTR, OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Its Competitors Nektar Therapeutics Omeros Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of NKTR or ASMB? 75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 5.3% of Nektar Therapeutics shares are held by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer NKTR or ASMB? Nektar Therapeutics presently has a consensus target price of $88.33, suggesting a potential upside of 284.73%. Assembly Biosciences has a consensus target price of $33.00, suggesting a potential upside of 79.35%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is NKTR or ASMB more profitable? Assembly Biosciences has a net margin of -124.15% compared to Nektar Therapeutics' net margin of -152.49%. Assembly Biosciences' return on equity of -131.77% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-152.49% -329.54% -55.24% Assembly Biosciences -124.15%-131.77%-36.81% Does the media prefer NKTR or ASMB? In the previous week, Nektar Therapeutics had 6 more articles in the media than Assembly Biosciences. MarketBeat recorded 8 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Nektar Therapeutics' average media sentiment score of 0.91 beat Assembly Biosciences' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, NKTR or ASMB? Nektar Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Which has stronger earnings and valuation, NKTR or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M2.89-$118.96M-$9.60-2.39Assembly Biosciences$32.15M4.37-$40.18M-$6.23-2.95 SummaryNektar Therapeutics beats Assembly Biosciences on 9 of the 16 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.90M$3.75B$5.49B$9.52BDividend YieldN/A1.17%4.73%4.09%P/E Ratio-2.959.2028.7823.81Price / Sales4.3711.89372.2066.04Price / CashN/A6.3535.4557.96Price / Book3.502.658.275.54Net Income-$40.18M-$109.62M$3.25B$259.28M7 Day Performance-0.81%-1.94%-3.70%-4.64%1 Month Performance0.55%8.51%4.34%4.41%1 Year Performance28.76%24.02%25.90%17.95% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.3751 of 5 stars$18.40+2.7%$33.00+79.3%+28.2%$136.90M$32.15M-2.95100Upcoming EarningsHigh Trading VolumeNKTRNektar Therapeutics4.236 of 5 stars$23.65-5.4%$88.33+273.5%+20.5%$310.17M$98.43M-2.46220News CoverageUpcoming EarningsOMEROmeros3.7085 of 5 stars$4.15+8.4%$18.00+333.7%-28.1%$224.41MN/A-1.57210News CoverageUpcoming EarningsGap UpHigh Trading VolumeCPIXCumberland Pharmaceuticals0.6006 of 5 stars$3.48-1.1%N/A+146.2%$52.59M$37.87M-13.9280Positive NewsUpcoming EarningsLLYEli Lilly and Company4.9108 of 5 stars$807.78-0.6%$1,012.56+25.4%-8.5%$770.22B$45.04B65.7347,000Trending NewsUpcoming EarningsJNJJohnson & Johnson4.6704 of 5 stars$166.18-1.3%$174.50+5.0%+4.1%$404.94B$88.82B17.77138,100Trending NewsAnalyst RevisionABBVAbbVie4.5744 of 5 stars$188.47-1.0%$211.29+12.1%+2.9%$336.11B$56.33B80.2055,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.4.997 of 5 stars$84.16-0.6%$108.69+29.1%-30.4%$212.71B$64.17B12.2575,000Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionPFEPfizer4.9528 of 5 stars$24.33-1.9%$28.55+17.3%-23.4%$140.94B$63.63B17.6381,000Trending NewsUpcoming EarningsBMYBristol Myers Squibb4.8702 of 5 stars$47.52-1.9%$58.53+23.2%-8.1%$98.56B$48.30B17.8034,100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionZTSZoetis4.9403 of 5 stars$150.65-1.0%$204.63+35.8%-19.2%$67.73B$9.29B27.0513,800Positive NewsUpcoming EarningsShort Interest ↑Analyst Revision Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Omeros Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Zoetis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
